Taro Pharmaceutical Industries Ltd. (TARO)
Stock Price Chart
Key Info
| Market Cap | 2.42B |
| Revenue (ttm) | 601.11M |
| Net Income (ttm) | -256.86M |
| Shares Out | 38.26M |
| EPS (ttm) | -6.70 |
| PE Ratio | n/a |
| Forward PE | 10.27 |
| Dividend | n/a |
| Dividend Yield | n/a |
Stock Quote
| Trading Day | Aug 6, 2020 |
| Last Price | $63.25 |
| Previous Close | $63.25 |
| Change ($) | 0.00 |
| Change (%) | 0.00% |
| Day's Open | - |
| Day's Range | 63.01 - 63.95 |
| Day's Volume | 0 |
| 52-Week Range | 56.07 - 99.69 |
More Stats
| Market Cap | 2.42B |
| Enterprise Value | 1.30B |
| Earnings Date (est) | Nov 10, 2020 |
| Ex-Dividend Date | n/a |
| Shares Outstanding | 38.26M |
| Float | 8.76M |
| EPS (basic) | -6.73 |
| EPS (diluted) | -6.70 |
| FCF / Share | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
| Payout Ratio | n/a |
| Shares Short | 128,993 |
| Short Ratio | 4.77 |
| Short % of Float | 1.47% |
| Beta | 0.90 |
| PE Ratio | n/a |
| Forward PE | 10.27 |
| P/FCF Ratio | n/a |
| PS Ratio | 4.03 |
| PB Ratio | 1.48 |
| Revenue | 601.11M |
| Operating Income | -268.17M |
| Net Income | -256.86M |
| Free Cash Flow | n/a |
| Net Cash | 1.12B |
| Net Cash / Share | 29.34 |
| Gross Margin | 66.50% |
| Operating Margin | -44.61% |
| Profit Margin | -42.70% |
| FCF Margin | n/a |
| ROA | 5.71% |
| ROE | -14.89% |
| ROIC | -17.90% |
Analyst Summary
Analyst Consensus: n/a
Financial Performance
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 645 | 670 | 662 | 879 | 951 | 863 | 759 | 671 | 543 | 506 |
| Revenue Growth | -3.75% | 1.21% | -24.73% | -7.51% | 10.18% | 13.65% | 13.16% | 23.55% | 7.4% | - |
| Gross Profit | 400 | 446 | 464 | 671 | 779 | 677 | 580 | 495 | 366 | 330 |
| Operating Income | 250 | 298 | 305 | 526 | 617 | 530 | 432 | 332 | 238 | 205 |
| Net Income | 244 | 282 | 211 | 456 | 541 | 484 | 360 | 266 | 204 | 183 |
| Shares Outstanding | 38.46 | 38.99 | 40.16 | 41.30 | 42.83 | 42.83 | 44.28 | 44.68 | 44.47 | 44.41 |
| Earnings Per Share | 6.35 | 7.23 | 5.26 | 11.05 | 12.62 | 11.31 | 8.14 | 5.95 | 4.59 | 4.11 |
| EPS Growth | -12.17% | 37.45% | -52.4% | -12.44% | 11.58% | 38.94% | 36.81% | 29.63% | 11.68% | - |
| Operating Cash Flow | 272 | 324 | 324 | 438 | 395 | 407 | 358 | 249 | - | 181 |
| Capital Expenditures | -26.61 | -27.02 | -25.81 | -27.25 | -18.97 | -19.78 | -21.24 | -9.47 | - | -5.86 |
| Free Cash Flow | 245 | 297 | 298 | 410 | 376 | 387 | 336 | 239 | - | 176 |
| Cash & Equivalents | 1,109 | 1,049 | 1,423 | 1,387 | 1,229 | 920 | 632 | 561 | 334 | 259 |
| Total Debt | - | - | - | - | - | 5.89 | 17.86 | 28.60 | 38.91 | 44.69 |
| Net Cash / Debt | 1,109 | 1,049 | 1,423 | 1,387 | 1,229 | 914 | 615 | 532 | 295 | 214 |
| Assets | 2,341 | 2,135 | 2,433 | 2,290 | 2,188 | 1,738 | 1,284 | 1,107 | 856 | 796 |
| Liabilities | 231 | 224 | 223 | 216 | 251 | 320 | 264 | 216 | 233 | 225 |
| Book Value | 2,104 | 1,906 | 2,205 | 2,067 | 1,931 | 1,412 | 1,016 | 886 | 619 | 567 |
Company Profile
Company Details
| Full Name | Taro Pharmaceutical Industries Ltd. |
| Country | Israel |
| Employees | 1,464 |
| CEO | Uday Vijaykumar Baldota |
Stock Information
| Ticker Symbol | TARO |
| Stock Exchange | New York Stock Exchange |
| Sector | Healthcare |
| Industry | Drug Manufacturers—Specialty & Generic |
| Unique Identifier | NYSE: TARO |
Description
Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products. It offers its products for various therapeutic categories comprises allergy, analgesic, antibacterial, antibiotic, anticonvulsant, antiemetic, antifungal, anti-inflammatory, anti-cancer, antiplatelet agent, antipyretic, cardiovascular, CNS, corticosteroid, cosmetic, cough and cold, dermatology, diuretic, endocrine, gastrointestinal, laxative, narcotics, neuropathic pain, neuropsychiatric, sedative/hypnotic, and topical anti-neoplastic. The company provides its products in the form of capsule, cream, drops, emulsion, gel/gel kit, granules, injectable, lotion, oil, ointment, paste, powder/powder for solution, rectal suppository, shampoo, solution/solution for infusion, spray, suspension, syrup, tablets, toothpaste and mouthwash, topical foam, and topical solution. It distributes and sells its products directly to wholesalers, retail drug store chains, food chains, mass merchandisers, grocery chains, and other direct purchasers and customers, as well as healthcare institutions and private pharmacies. The company was founded in 1959 and is based in Haifa Bay, Israel. Taro Pharmaceutical Industries Ltd. is a subsidiary of Alkaloida Chemical Company Exclusive Group Ltd.